Search results for: Health Policy and Regulation
Filter search results
Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. In a previous publication we presented a…
Alcohol: Reducing the Harm
1 April 1981
…associated with alcohol use in Britain is probably in the order of 5,000 to 10,000 per annum and official claims that between 500,000 and 750,000 people in England and Wales…
The Market for Biosimilars: Evolution and Policy Options
1 November 2008
…and other payers also should encourage pharmacovigilance and other outcomes studies that produce the PSY data that will encourage interchangeability and greater price competition. Over time, biosimilar markets can become…
Margaret Kyle
3 February 2023
…published in various journals of economics, strategy, health policy and competition policy, including the Quarterly Journal of Economics, RAND Journal of Economics, Review of Economics and Statistics, Journal of Law…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of the University of York…
New Publications: Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
18 April 2018
…decisions and outcomes-based contracting. The focus of the 2017 ICER Policy Summit was on RWE for HTA assessments and payer coverage decisions – both initial decisions and reassessments – and…
Policy Options for Formulary Development in Middle-income Countries
1 January 2017
…medicines for formulary inclusion. This report presents a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the health system organisation and its priority setting), and…